Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club

International Journal of Clinical Practice

Volumn 63, Issue 1, 2009, Pages 19-26

  Bergmann, P ^a   Body, J J ^a   Boonen, S ^b   Boutsen, Y ^c   Devogelaer, J P ^d   Goemaere, S ^e   Kaufman, J M ^e   Reginster, J Y ^f   Gangji, V ^g  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f ULg Liège   (Belgium)

^g ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; IBANDRONIC ACID; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE; PYRIDINOLINE; RISEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; EVIDENCE BASED MEDICINE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SELECTION; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VERTEBRA FRACTURE;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; DIPHOSPHONATES; EVIDENCE-BASED MEDICINE; FALSE NEGATIVE REACTIONS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; RISK FACTORS;

EID: 57649200194     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01911.x     Document Type: Conference Paper

References (56)

1. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993 94 : 646 50.
2. Van Hoof VO, Hoylaerts MF, Geryl H et al. Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis. Clin Chem 1990 36 : 875 8.
3. Broyles DL, Nielsen RG, Bussett EM et al. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 1998 44 : 2139 47.
4. Gundberg CM, Markowitz ME, Mizruchi M et al. Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 1985 60 : 736 9.
5. Delmas PD, Wilson DM, Mann KG et al. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 1983 57 : 1028 30.
6. Diaz Diego EM, Guerrero R, de la Piedra C. Six osteocalcin assays compared. Clin Chem 1994 40 : 2071 7.
7. Blumsohn A, Hannon RA, Eastell R. Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin Chem 1995 41 : 318 9.
8. Melkko J, Niemi S, Ristelli L et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990 36 : 1328 32.
9. Melkko J, Kauppila S, Niemi S et al. Immunoassay for intact amino-terminal propeptide of human type 1 procollagen. Clin Chem 1996 42 : 947 54.
10. Brandt J, Krogh TN, Jensen CH et al. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 1999 45 : 47 53.
11. Scariano JK, Garry PJ, Montoya GD et al. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. Clin Biochem 2001 34 : 639 44.
12. Uebelhart D, Schlemmer A, Johansen JS et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991 72 : 367 73.
13. Garnero P, Gineyts E, Arbault P et al. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995 10 : 641 9.
14. Ristelli J, Niemi S, Elomaa I et al. Bone resorption assay based on a peptide liberated during type I collagen degradation. J Bone Miner Res 1991 6 : S251.
15. Bonde M, Garnero P, Fledelius C et al. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997 12 : 1028 34.
16. Hanson DA, Weis MA, Bollen AM et al. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptide in urine. J Bone Miner Res 1992 7 : 1251 8.
17. Nagant de Deuxchaisnes C, Devogelaer JP. Endocrinological status of postmenopausal osteoporosis. Clin Rheum Dis 1986 12 : 559 635.
18. Devogelaer JP. How do you know who needs prevention or treatment? Baillières Clin Rheumatol 1997 11 : 539 63.
19. Garnero P, Sornay-Rendu E, Chapuy MC et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996 11 : 337 49.
20. Dresner-Pollak R, Parker RA, Poku M et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 1996 59 : 328 33.
21. Recker R, Lappe J, Davies KM et al. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004 19 : 1628 33.
22. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998 13 : 297 302.
23. Hansen MA, Overgaard K, Riis BJ et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991 303 : 961 4.
24. Garnero P, Sornay-Rendu E, Duboeuf F et al. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999 14 : 1614 21.
25. Boonen S, Body JJ, Boutsen Y et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2005 16 : 239 54.
26. Lenora J, Ivaska KK, Obrant KJ et al. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007 18 : 1297 305.
27. Melton LJ III., Khosla S, Atkinson EJ et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997 12 : 1083 91.
28. Reginster JY, Henrotin Y, Christiansen C et al. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 2001 69 : 130 7.
29. Marshall D, Johnell O, Wedel H et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996 312 : 1254 9.
30. van Daele PL, Seibel MJ, Burger H et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 1996 312 : 482 3.
31. Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996 11 : 1531 8.
32. Garnero P, Sornay-Rendu E, Claustrat B et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000 15 : 1526 36.
33. Ross PD, Kress BC, Parson RE et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000 11 : 76 82.
34. Sornay-Rendu E, Munoz F, Garnero P et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005 20 : 1813 9.
35. Chapurlat RD, Garnero P, Bréart G et al. Serum type 1 collagen breakdown products (serum CTX) predicts hip fracture in elderly women: the EPIDOS study. Bone 2000 27 : 283 6.
36. Szulc P, Chapuy MC, Meunier PJ et al. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996 5 : 487 8.
37. Vergnaud P, Garnero P, Meunier PJ et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997 82 : 719 24.
38. Schousboe JT, Bauer DC, Nyman JA et al. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of facture for bisphosphonate therapy. Osteoporos Int 2007 18 : 201 10.
39. Bauer DC, Garnero P, Hochberg MC et al. Pretreatment levels of bone turnover and antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006 21 : 292 9.
40. Seibel MJ, Naganathan V, Barton I et al. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004 19 : 323 9.
41. Seibel MJ. Biochemical markers of bone turnover part II: Clinical applications in the management of osteoporosis. Clin Biochem Rev 2006 27 : 123 38.
42. Ravn P, Hosking D, Thompson D et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the Early Postmenopausal Intervention Cohort study. J Clin Endocrinol Metab 1999 84 : 2363 8.
43. Fink E, Cormier C, Steinmetz P et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000 11 : 295 303.
44. Bauer DC, Black DM, Garnero P et al. Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004 19 : 1250 8.
45. Eastell R, Barton I, Hannon RA et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003 18 : 1051 6.
46. Delmas PD, Recker RR, Chesnut CH et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004 15 : 792 8.
47. Reginster JY, Gieschke R. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Curr Drug Metab 2006 7 : 827 36.
48. Reginster JY, Adami S, Lakatos P et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006 65 : 654 61.
49. Reginster JY, Felsenberg D, Cooper C et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 2006 17 : 159 66.
50. Papapoulos SE, Schimmer RC. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy:implications from clinical studies with ibandronate. Ann Rheum Dis 2007 66 : 853 8.
51. Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: useful or not? J Endocrinol Invest 2003 26 : 464 71.
52. Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004 89 : 1117 23.
53. Delmas PD, Vrijens B, Eastell R et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007 92 : 1296 304.
54. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001 47 : 1443 50.
55. Seibel MJ. Biochemical markers of bone turnover. Part I: Biochemistry and variability. Clin Biochem Rev 2005 26 : 97 122.
56. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000 11 (Suppl. 6 S30 44.